Abstract
Phosphoproteomic networks mediated by protein kinases are the key drivers of proliferative and survival signals underlying human cancers, and as such a number of kinases have been the subject of intensive drug discovery efforts. A key question that must be answered during clinical development is whether a kinase inhibitor is effectively inhibiting its appropriate target kinase and pathway in the tumor. Reverse-phase protein arrays (RPMAs) offer the ability to analyze behavior of entire signaling networks in response to drug treatment and thus have promise as a technology for monitoring cellular response to kinase inhibitors. We have shown that it is possible to use RPMAs to detect phosphorylation changes in key multiple signaling pathway proteins in response to targeted inhibitors of EGFR, MEK, and PI3 kinase.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Grant, S. K. (2009) Therapeutic Protein Kinase Inhibitors, Cell. Mol. Life Sci, 66(7), 1163–1177.
Zhang, J., Yang, P. L., and Gray, N. S. (2009) Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer 9, 28–39.
Kohno, M., and Pouyssegur, J. (2006) Targeting the ERK signaling pathway in cancer therapy. Ann. Med. 38, 200–211.
Ihle, N. T., and Powis, G. (2009) Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy. Mol. Cancer Ther. 8, 1–9.
Carnero, A., Blanco-Aparicio, C., Renner, O., Link, W., and Leal, J. F. (2008) The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr. Cancer Drug Tar. 8, 187–198.
Bareschino, M. A., Schettino, C., Troiani, T., Martinelli, E., Morgillo, F., and Ciardiello, F. (2007) Erlotinib in cancer treatment., Ann. Oncol. 18 Suppl 6, vi35–41.
Brown, A. P., Carlson, T. C., Loi, C. M., and Graziano, M. J. (2007) Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration. Cancer Chemoth. Pharm. 59, 671–679.
Folkes, A. J., Baker, S. J., Chuckowree, I. S., Eccles, S. A., Hayes, A., Hancox, T. C., Latif, M. A., Olivero, A. G., Patel, S., and Shuttleworth, S. J. (2008) The discovery of GDC-0941: A potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. in AACR Annual Meeting, San Diego.
Espina, V., Wulfkuhle, J., Calvert, V. S., Liotta, L. A., and Petricoin, E. F., 3rd. (2008) Reverse phase protein microarrays for theranostics and patient-tailored therapy. In Methods in molecular biology (Clifton, N.J) 441, 113–128.
Wulfkuhle, J. D., Edmiston, K. H., Liotta, L. A., and Petricoin, E. F., 3 rd. (2006) Technology insight: pharmacoproteomics for cancer – promises of patient-tailored medicine using protein microarrays. Nat. Clin. Pract. Oncol. 3, 256–268.
Espina, V., Wulfkuhle, J. D., Calvert, V. S., Petricoin, E. F., 3rd, and Liotta, L. A. (2007) Reverse phase protein microarrays for monitoring biological responses. In Methods in molecular biology (Clifton, N.J) 383, 321–336.
Boyd, Z. S., Wu, Q. J., O’Brien, C., Spoerke, J., Savage, H., Fielder, P. J., Amler, L., Yan, Y., and Lackner, M. R. (2008) Proteomic analysis of breast cancer molecular subtypes and biomarkers of response to targeted kinase inhibitors using reverse-phase protein microarrays. Mol. Cancer Ther. 7, 3695–3706.
Secrist, J. P., Burns, L. A., Karnitz, L., Koretzky, G. A., and Abraham, R. T. (1993) Stimulatory effects of the protein tyrosine phosphatase inhibitor, pervanadate, on T-cell activation events. J. Biol. Chem. 1993 Mar 15;268(8), 5886–5893.
Steinberg, T. H., Jones, L. J., Haugland, R. P., and Singer, V. L. (1996) SYPRO orange and SYPRO red protein gel stains: one-step fluorescent staining of denaturing gels for detection of nanogram levels of protein, Anal Biochem. 239(2), 223–237.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Lavezzari, G., Lackner, M.R. (2012). Monitoring Phosphoproteomic Response to Targeted Kinase Inhibitors Using Reverse-Phase Protein Microarrays. In: Kuster, B. (eds) Kinase Inhibitors. Methods in Molecular Biology, vol 795. Humana Press. https://doi.org/10.1007/978-1-61779-337-0_14
Download citation
DOI: https://doi.org/10.1007/978-1-61779-337-0_14
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-61779-336-3
Online ISBN: 978-1-61779-337-0
eBook Packages: Springer Protocols